Jazz Pharmaceuticals

Yahoo Finance • 13 days ago

Jazz Pharmaceuticals plc (JAZZ) Wins FDA Nod for Modeyso in Rare Pediatric Brain Tumors

In this article, we will be taking a look at the 12 Cheap Healthcare Stocks to Buy Now. Jazz Pharmaceuticals plc stands ninth among them. Jazz Pharmaceuticals plc (NASDAQ:JAZZ), a global biopharmaceutical leader, develops and commercializ... Full story

Yahoo Finance • 18 days ago

Amneal wins FDA nod for generic targeting Jazz Pharma’s Xyrem

[FDA Seal of Approval and Rubber Stamp] asbe/iStock via Getty Images Amneal Pharmaceuticals (NASDAQ:AMRX [https://seekingalpha.com/symbol/AMRX]) announced on Thursday that the U.S. Food and Drug Administration (FDA) approved its generic p... Full story

Yahoo Finance • 19 days ago

Chronic Myelomonocytic Leukemia Market Analysis and Forecast Report 2025-2035, with Profiles of AbbVie, GlaxoSmithKline, Incyte, Jazz Pharmaceuticals, Novartis, Stemline Therapeutics, and More

Company Logo The global chronic myelomonocytic leukemia (CMML) market is set for significant growth due to rising CMML cases, advanced targeted therapies, and increased disease awareness. Recognized as a rare leukemia, CMML's prevalence,... Full story

Yahoo Finance • last month

Jazz Pharmaceuticals Enters Into Global License Agreement To Develop SAN2355

(RTTNews) - Jazz Pharmaceuticals plc (JAZZ), Wednesday announced a global license agreement with Denmark-based Saniona to obtain exclusive worldwide rights to develop SAN2355, a preclinical, selective small molecule activator for epilepsy... Full story

Yahoo Finance • last month

Ligand to Participate in September Investor Conferences

JUPITER, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcom... Full story

Yahoo Finance • 2 months ago

BofA Securities raises Jazz Pharmaceuticals stock price target on Modeyso potential

Investing.com - BofA Securities has raised its price target on Jazz Pharmaceuticals (NASDAQ:JAZZ) to $225.00 from $217.00 while maintaining a Buy rating ahead of the company’s upcoming investor webcast. The new target aligns with the broad... Full story

Yahoo Finance • 2 months ago

Onco360 adds Modeyso™ (dordaviprone) to portfolio of Oncology and Rare Cancer therapies as a National Specialty Pharmacy Provider

LOUISVILLE, Ky., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Jazz Pharmaceuticals for Modeyso™ (dordaviprone). It is indicated for the treatm... Full story

Yahoo Finance • 2 months ago

Psychedelic Drugs Market Size to Surpass USD 10.11 Billion by 2032, Fueled by Breakthrough Therapies and Expanding Mental Health Applications – SNS Insider

Austin, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Psychedelic Drugs Market Size & Growth Outlook According to SNS Insider, the global Psychedelic Drugs Market was valued at USD 3.63 billion in 2024 and is projected to reach USD 10.11 billion by... Full story

Yahoo Finance • 2 months ago

US FDA approves Jazz Pharma's drug for rare brain tumor

By Padmanabhan Ananthan and Puyaan Singh (Reuters) -The U.S. Food and Drug Administration said on Wednesday that it has approved Jazz Pharmaceuticals (NASDAQ:JAZZ)’ drug to treat diffuse midline glioma, a rare and aggressive tumor, in a... Full story

Yahoo Finance • 2 months ago

JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) Recognized as a Decent Value Stock with Strong Fundamentals

Jazz Pharmaceuticals Plc (NASDAQ:JAZZ [https://www.chartmill.com/stock/quote/JAZZ]) has been recognized through a "Decent Value" screening method, which focuses on stocks with solid fundamental valuations while maintaining reasonable profi... Full story

Yahoo Finance • 2 months ago

Jazz Pharmaceuticals projects late Q4 zanidatamab Phase III data, signals leadership transition and updates 2025 guidance

Earnings Call Insights: Jazz Pharmaceuticals (JAZZ) Q2 2025 MANAGEMENT VIEW * Bruce C. Cozadd, Chairman and CEO, announced Renee D. Gala's appointment as President and CEO effective August 11, stating "I'm confident Renee is the right... Full story

Yahoo Finance • 2 months ago

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Reports Q2 2025 Earnings Miss and Leadership Transition

Jazz Pharmaceuticals Plc (NASDAQ:JAZZ [https://www.chartmill.com/stock/quote/JAZZ/profile]) reported its second-quarter 2025 financial results, missing analyst expectations on both revenue and earnings per share (EPS). The company also ann... Full story

Yahoo Finance • 3 months ago

Deutsche Bank initiates Jazz Pharmaceuticals stock with Buy rating

Investing.com - Deutsche Bank initiated coverage on Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy rating and a price target of $152.00 on Tuesday. The company, currently trading at a P/E ratio of 14.2x and maintaining impressive gross pr... Full story

Yahoo Finance • 3 months ago

Jazz Pharmaceuticals (JAZZ) Highlights Growth at Goldman Sachs Healthcare Conference

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) is one of the 7 most undervalued pot stocks to buy according to analysts. On June 11, the company presented at the Goldman Sachs 46th Annual Global Healthcare Conference, where it outlined its strateg... Full story

Yahoo Finance • 3 months ago

Avadel Pharmaceuticals Receives Unanimous Appeals Court Affirmation for LUMRYZ FDA Approval

Avadel Pharmaceuticals (NASDAQ:AVDL) is one of the most undervalued small-cap stocks to buy according to analysts. On June 30, Avadel Pharmaceuticals announced that the US Court of Appeals for the District of Columbia Circuit (Appeals Cour... Full story

Yahoo Finance • 3 months ago

Jazz Pharmaceuticals Picks Renee Gala As CEO

(RTTNews) - Jazz Pharmaceuticals plc (JAZZ), Thursday announced the decision to appoint Chief Operating Officer Renee Gala as the company's President and Chief Executive Officer, effective August 11, 2025. The decision comes as CEO Bruce... Full story

Yahoo Finance • 3 months ago

Nuevocor Strengthens Board with Appointment of Thierry Abribat

SINGAPORE, July 7, 2025 /PRNewswire/ -- Nuevocor, a Singapore-headquartered biotechnology company developing cures for cardiomyopathies driven by aberrant mechanobiology, today announced the appointment of Dr. Thierry Abribat to its Board... Full story

Yahoo Finance • 3 months ago

PharmaMar FY 2024 slides: Revenue up 11%, net profit soars amid clinical advances

Introduction & Market Context Spanish biopharmaceutical company PharmaMar presented its full-year 2024 results on February 28, 2025, highlighting significant financial improvements and clinical development milestones. The company, which s... Full story

Yahoo Finance • 3 months ago

Zymeworks stock holds steady as H.C. Wainwright reiterates Neutral rating

Investing.com - H.C. Wainwright has reiterated its Neutral rating and $13.00 price target on Zymeworks (NASDAQ:ZYME) following recent developments with its zanidatamab therapy. The company, currently trading near $12.89, has delivered an i... Full story

Yahoo Finance • 3 months ago

Jazz Pharma Says EU Grants Conditional MA To Ziihera For Advanced HER2-Positive Biliary Tract Cancer

(RTTNews) - Jazz Pharmaceuticals plc (JAZZ) announced Tuesday that the European Commission (EC) has granted conditional marketing authorization for Ziihera (zanidatamab), a dual human epidermal growth factor receptor 2 (HER2)-targeted bisp... Full story